抗肺炎球菌荚膜抗体作为实验性肺炎球菌脑膜炎辅助治疗的评估
Evaluation of anti-pneumococcal capsular antibodies as adjunctive therapy in experimental pneumococcal meningitis.
作者信息
Brandt Christian T, Frimodt-Møller Niels, Lundgren Jens D, Pedersen Michael, Skovsted Ian C, Rowland Ian J, Østergaard Christian
机构信息
National Center for Antimicrobials and Infection Control, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark.
出版信息
J Antimicrob Chemother. 2006 Dec;58(6):1291-4. doi: 10.1093/jac/dkl401. Epub 2006 Oct 26.
OBJECTIVE
Bacteraemia concomitant with meningitis has been shown to greatly affect outcome. Consequently, the efficacy of serotype-specific anti-pneumococcal antiserum (APAS) was investigated in a rat model of pneumococcal meningitis.
METHODS
Rats were infected with Streptococcus pneumoniae serotype 3. All rats received ceftriaxone starting 26 h post-infection. APAS was administered either at the time of infection or 26 h post-infection and effects were compared with rats treated with antibiotics only.
RESULTS AND CONCLUSION
A significant clinical benefit was found when APAS was given at the time of infection whereas no effect was found when administered 26 h after infection. This work indicates that the clinical value of using APAS in pneumococcal meningitis may be limited.
目的
已表明菌血症合并脑膜炎会极大地影响预后。因此，在肺炎球菌脑膜炎大鼠模型中研究了血清型特异性抗肺炎球菌抗血清（APAS）的疗效。
方法
用3型肺炎链球菌感染大鼠。所有大鼠在感染后26小时开始接受头孢曲松治疗。APAS在感染时或感染后26小时给药，并将其效果与仅用抗生素治疗的大鼠进行比较。
结果与结论
在感染时给予APAS可发现显著的临床益处，而在感染后26小时给药则未发现效果。这项研究表明，在肺炎球菌脑膜炎中使用APAS的临床价值可能有限。
Zotero 插件